Patented biomarker for cardiac injury. 

The development and application of a high-sensitivity immunoassay for cMyC

Background

Cardiac myosin–binding protein C (cMyC) is a protein with cardiac-restricted expression that we have previously shown appears in the systemic circulation after acute myocardial injury using a relatively insensitive assay. This article describes a high-sensitivity assay for cMyC, which demon- strates that it can be measured at baseline in almost all individuals, and in a stable population its concentration correlates with those for cTnI and cTnT.

Conclusion

We have developed and validated a sensitive assay for cMyC, which for the first time allows this cardiac-specific marker of myocardial injury to be quantified in ambulatory patients. The diagnostic performance of this assay is yet to be compared with cTnI and cTnT in the setting of NSTE-ACS.
Distribution of cMyC, cTnI, and cTnT concentrations among 359 patients referred for elective coronary angiography with a cTnT ,14 ng/L.